Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07784101 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT07784101 · ClinicalTrials.gov record · last posted 2026-08-25

A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).

Name: A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL). — clinical trial record (NCT07784101)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 3

SponsorBeijing InnoCare Pharma Tech Co., Ltd.

Started2026-10

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This study aims to compare the efficacy and safety of ICP-248 in combination with orelabrutinib versus pirtobrutinib in patients with relapsed or refractory mantle cell lymphoma (r/r MCL).

Trial Details

NCT Number	NCT07784101
Lead Sponsor	Beijing InnoCare Pharma Tech Co., Ltd.
Conditions	Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Enrollment	280 participants
Start Date	2026-10
Primary Completion	2032-10 (estimated)
Study Completion	2033-12 (estimated)
Updated on ClinicalTrials.gov	2026-08-25